ZURA Stock Summary and Trading Ideas (Zura Bio Limited - Class A | NASDAQ:ZURA)

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Zura Bio Limited - Class A trades on the NASDAQ stock market under the symbol ZURA.

As of March 24, 2026, ZURA stock price declined to $5.38 with 475,760 million shares trading.

ZURA has a beta of 1.64, meaning it tends to be more sensitive to market movements. ZURA has a correlation of 0.07 to the broad based SPY ETF.

ZURA has a market cap of $510.46 million. This is considered a Small Cap stock.

In the last 3 years, ZURA traded as high as $33.49 and as low as $.97.

The top ETF exchange traded funds that ZURA belongs to (by Net Assets): VXF, IWC, SBIO, AVSC.

ZURA has outperformed the market in the last year with a return of +298.5%, while the SPY ETF gained +15.1%. In the last 3 month period, ZURA beat the market returning +19.6%, while SPY returned -5.1%. However, in the most recent 2 weeks ZURA has underperformed the stock market by returning -22.0%, while SPY returned -3.3%.

ZURA support price is $5.28 and resistance is $5.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZURA shares will trade within this expected range on the day.